不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>Gen9收到安捷伦2100万美元股权投资

Gen9收到安捷伦2100万美元股权投资

安捷伦2013年4月25日 11:29 点击:1617

安捷伦 Agilent.  Gen9

2013年4月24日,安捷伦公司宣布对合成生物学公司Gen9进行股权投资,投资金额为2100万美元。

  ANJIELUNZAILIANHESHENGMINGZHONGSHUO,GAIXIANGTOUZIJIANGYONGYUCHANPINKAIFAHEKUOZHANQISHANGYEJICHUSHESHI。SIRENCHIYOUGen9 YOUMASHENGLIGONGXUEYUANJoseph Jacobson2009NIANCHUANGJIAN,TAYIJINGKAIFADEJIYINHECHENGJISHU,KESHIXIANBIXIANQIANFANGFAGENGDICHENGBEN、GENGGAOJINGDU,YIGAOTONGLIANG、ZIDONGHUAFANGSHIHECHENGDNAJIEGOU。TADEBioFabPINGTAINENGGOUHECHENGSHUWANCHENGQIANSHANGWANDEJIYINPIANDUAN,TONGSHISUOXUDESHIYANSHIKONGJIANJINXUJIPINGFANGYINGCHI。

  ANJIELUNHUODELEGen 9GONGSIDEGUQUAN,JUTIGUQUANSHULIANGMEIYOUPILU,CIWAI,ANJIELUNJIANGZAIGen9GONGSIZHONGHUODEYIWEIDONGSHIHUICHENGYUANXIWEI。

  CIWAI,ZUOWEIHEZUOGUANXIDEYIBUFEN,Gen9JIANGBAANJIELUNGUAHEGANSUANHECHENGJISHUZHENGHERUQISHENGCHANGUOCHENGZHONG,YUNXUCHUANGZAODAGUIMOJIEGOUTONGLUHEDNASHUJUKU。MUQIANGen9ZHIZAOHEXIAOSHOUQIZIJIDESHUANGLIANGeneBits DNAJIEGOU,500DAO1024GEJIANJIDUIDEJIYINPIANDUANZHANG。

  “ANJIELUNDETOUZISHIDUIWOMENDEZHUANYOUBioFabPINGTAIDEQIANGDAZHENGMING,WOMENQIDAIYUANJIELUNMIQIEHEZUO,BINGWEIRAOWOMENDEZHIZAONENGLIJINYIBUCHUANGXIN,JIANGGen9DAZAOCHENGWEIGAOTONGLIANGHECHENGSHENGWUXUESHICHANGDELINGXIANGONGYINGSHANG。”Gen9ZONGCAIJIANSHOUXIZHIXINGGUANKevin MunnellySHUO。

  对于安捷伦,合作扩展我们在合成生物学领域的市场占有率。去年,安捷伦向加州大学伯克利分校合成生物学研究所进行了投资,成为该研究所第一家公司成员。先前安捷伦还在哈佛大学韦斯研究生物启发工程投资。

 

Gen9 Receives $21 Million Strategic Investment from Agilent Technologies

Agilent's Equity Stake Will Accelerate Growth and Innovation at Company Pioneering Next-Generation Gene Synthesis

CAMBRIDGE, Mass. and SANTA CLARA, Calif., April 24, 2013

不用本金就能赚钱的方法Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing genes, and Agilent Technologies (NYSE: A) today announced the closing of a $21 million strategic investment from Agilent in Gen9. Gen9 will use these funds to further invest in product development and to expand the commercial infrastructure for its synthetic biology business. As part of this investment, Agilent has secured an equity stake in the company and will join its board of directors.

不用本金就能赚钱的方法Gen9 is a privately held company with a portfolio of next-generation gene synthesis technologies that enable the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods. Together, these technologies form the foundation of the Gen9 BioFab(r) platform, which has the capacity to synthesize tens of thousands of gene fragments in just a few square feet of laboratory space.

不用本金就能赚钱的方法As part of this relationship, Gen9 will incorporate Agilent's Oligonucleotide Library Synthesis (OLS) technology into its manufacturing process to allow for the large-scale creation of pathway constructs and DNA libraries. Agilent's OLS technology is the industry-leading platform for generating high-accuracy oligos. Today, Gen9 is manufacturing and shipping double-stranded GeneBits(tm) DNA constructs, or gene fragments from 500 to 1,024 base pairs long.

"Gen9 was founded to significantly increase the world's capacity to cost-effectively generate high-quality DNA content for use in transforming industries ranging from chemical and enzyme production to agriculture, biofuels, pharmaceuticals, and even data storage," said Kevin Munnelly, president and CEO of Gen9, Inc. "Agilent's investment is a powerful validation of our proprietary BioFab platform and we look forward to working closely with them to further innovate around our manufacturing capabilities and build Gen9 into the leading high-throughput supplier to the synthetic biology marketplace."

不用本金就能赚钱的方法"Synthetic DNA constructs have the potential to form the foundation of the next revolution in industrial manufacturing, through biologically constructed machines that can produce materials of high value and complexity. This revolution will only be possible through the ability to routinely synthesize and assemble high-quality, error-free DNA at much greater sequence lengths than are currently available," added Neil Cook, vice president and director, Agilent Laboratories. "We believe that Gen9 has the correct strategy, technology, team, and IP portfolio to complement Agilent's innovations in oligo library synthesis and, working together, we will help realize the promise of synthetic biology."

Agilent's partnership with Gen9 complements the company's existing investments in synthetic biology, gene synthesis and assembly, including further generations of its oligo synthesis technology. Agilent currently produces the highest-quality long DNA compared to that of any commercially available source. In addition, in 2011 Agilent launched a collaborative investment with UC Berkeley's Synthetic Biology Institute as its first Industry Member. Agilent announced an earlier collaborative investment with Harvard University's Wyss Institute for Biologically Inspired Engineering in 2010.

不用本金就能赚钱的方法Gen9 was founded in 2009 by Joseph Jacobson (Massachusetts Institute of Technology), George Church (Harvard Medical School) and Drew Endy (Stanford University). Additional Gen9 investors include Draper Fisher Jurvetson, The Kraft Group, PBM Capital Group and a number of angel investors, including Scott A. Schoen and Weili Dai.

For more information, please visit .


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at .

About Gen9

Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world's capacity to produce DNA content. The privately held company's next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is based in Cambridge, Mass., and can be found online at .

不用本金就能赚钱的方法Gen9, GeneBits and BioFab are trademarks or registered trademarks of Gen9, Inc.

# # #

Contact:

Colin Sanford
Gen9
+1 203 340 2441
colin@bioscribe.com

Eric Endicott
Agilent Technologies Inc.
+ 1 408 553 2005
eric_endicott@agilent.com

(来源: 安捷伦 )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图